AI-generated research brief — verify at source
Neoadjuvant GOLP Regimen More Than Doubles Event-Free Survival in Resectable High-Risk Intrahepatic Cholangiocarcinoma
In a randomised phase 2–3 trial, patients with resectable high-risk intrahepatic cholangiocarcinoma who received neoadjuvant GOLP (gemcitabine-oxaliplatin, lenvatinib, and the PD-1 inhibitor toripalimab) before surgery had a median event-free survival of 18.0 months, compared with 8.7 months in patients who proceeded directly to surgery — a difference that was statistically significant. The overall survival benefit was also clinically substantial, though it did not meet the pre-specified statistical threshold at this interim analysis.
What Was Studied
This trial asked whether adding a multi-agent neoadjuvant regimen — combining platinum-based chemotherapy, a tyrosine kinase inhibitor, and immune checkpoint blockade — before curative-intent surgery could improve outcomes in patients with resectable intrahepatic cholangiocarcinoma carrying high-risk features for recurrence. This disease has historically lacked any established neoadjuvant standard of care, and recurrence after resection remains a leading cause of treatment failure.
How It Was Studied
This was a randomised phase 2–3 trial enrolling 178 patients with resectable high-risk intrahepatic cholangiocarcinoma across what appears to be a Chinese tertiary centre setting (funded in part by the Shanghai Hospital Development Center). Patients were assigned in a 1:1 ratio to either the neoadjuvant GOLP group (88 patients) or the direct surgery control group (90 patients). The neoadjuvant regimen consisted of intravenous gemcitabine-oxaliplatin plus toripalimab every three weeks for three cycles, combined with daily oral lenvatinib over nine weeks, followed by curative resection. Both groups then received adjuvant capecitabine for eight cycles post-surgery. The primary endpoint was event-free survival, with overall survival and safety as secondary endpoints. The results reported here reflect a pre-planned interim analysis conducted at a median follow-up of 16.9 months.
What Was Observed
- Neoadjuvant GOLP more than doubled median event-free survival. Patients in the neoadjuvant group had a median event-free survival of 18.0 months (95% CI, 13.8 to 27.6) versus 8.7 months (95% CI, 7.2 to 12.4) in the control group, a difference that was highly statistically significant (P < 0.001), indicating the result is very unlikely to be due to chance.
- A meaningful overall survival advantage was observed but did not cross the interim significance boundary. At 24 months, 79% of patients in the neoadjuvant group were alive (95% CI, 70 to 90) compared with 61% in the control group (95% CI, 50 to 75), representing approximately 57% lower risk of death (hazard ratio 0.43; 95% CI, 0.23 to 0.79; P = 0.005). However, this did not satisfy the pre-specified interim significance criterion of a two-sided alpha of 0.0019, meaning overall survival conclusions remain provisional.
- The neoadjuvant regimen carried a higher overall adverse event burden, though serious toxicity was limited. Grade 3 or higher adverse events occurred in 28% of neoadjuvant patients during the pre-surgical phase, with treatment-related grade 3 or higher events in 26%. Importantly, no treatment-related deaths were reported, and the majority of adverse events across all phases were low-grade.
Why This Matters
Intrahepatic cholangiocarcinoma carries a poor prognosis even after resection, and no neoadjuvant regimen has previously been established as effective in this setting. This trial provides the first randomised evidence that a chemotherapy-immunotherapy-targeted therapy combination can substantially extend event-free survival before surgery. The findings are likely to intensify investigation into neoadjuvant strategies across biliary tract cancers more broadly.
How to Read This Result
Although the event-free survival result is compelling, this is an interim analysis with a relatively short median follow-up, and overall survival data remain immature and below the pre-specified significance threshold, warranting caution before drawing definitive conclusions about long-term benefit.
Limitations
The abstract does not explicitly report study limitations. However, the interim nature of the analysis, the single-country setting, and the fact that the overall survival endpoint did not meet its pre-specified significance criterion are notable constraints on the scope of conclusions that can be drawn at this stage.